Aclaris Therapeutics, Inc. (ACRS) vs ProKidney Corp. (PROK)
A side-by-side comparison of Aclaris Therapeutics, Inc. and ProKidney Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRS
Aclaris Therapeutics, Inc.
$3.93HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
PROK
ProKidney Corp.
$1.60HealthcareDelayed quote: Oct 6, 2026, 12:14 PM EDT
Total return — ACRS vs PROK
growth of $100 · dividends reinvested · last 5yACRS -75.7% (-24.6%/yr)PROK -84.4% (-31.0%/yr)ACRS compounded faster over this window
ACRS PROK
ACRS vs PROK: by the numbers
- •ACRS is the larger company ($549M vs $536M market cap).
- •Both run net losses; ACRS's is the smaller (-921.50% vs -10599.76% net margin).
Metrics side by side
Valuation
| Metric | ACRS | PROK |
|---|---|---|
| P/S ratio | 66.84 | 655.65 |
| P/B ratio | 4.41 | N/A |
Profitability
| Metric | ACRS | PROK |
|---|---|---|
| Gross margin | 73.28% | 100.00% |
| Operating margin | -975.91% | -18477.83% |
| Net margin | -921.50% | -10599.76% |
| ROE | -60.79% | N/A |
| ROIC | -56.99% | -78.31% |
Growth (annualized)
| Metric | ACRS | PROK |
|---|---|---|
| Revenue CAGR (5Y) | 4.39% | N/A |
| Total return CAGR (5Y) | -24.23% | -30.65% |
Frequently asked
- How have ACRS and PROK total returns compared?
- Over the past 5 years, ACRS delivered -24.23% and PROK delivered -30.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.